PubRank

Alberto Albanese

Author PubWeight™ 109.36‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004 15.91
2 Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004 4.56
3 Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2004 2.90
4 The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 2013 2.65
5 Transportin-SR2 imports HIV into the nucleus. Curr Biol 2008 2.35
6 PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol 2004 2.30
7 Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord 2010 2.20
8 Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. Arch Neurol 2008 1.96
9 Red flags for multiple system atrophy. Mov Disord 2008 1.75
10 Mitochondrial DNA haplogroup K is associated with a lower risk of Parkinson's disease in Italians. Eur J Hum Genet 2005 1.71
11 PARK6-linked parkinsonism occurs in several European families. Ann Neurol 2002 1.68
12 Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants. Brain 2010 1.66
13 Effectiveness of higher doses of botulinum toxin to induce healing in patients with chronic anal fissures. Surgery 2002 1.65
14 Primary dystonia and dystonia-plus syndromes: clinical characteristics, diagnosis, and pathogenesis. Lancet Neurol 2011 1.62
15 Progressive supranuclear palsy and Parkinson's disease in a family with a new mutation in the tau gene. Ann Neurol 2004 1.51
16 Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann Neurol 2002 1.51
17 A case of dementia parkinsonism resembling progressive supranuclear palsy due to mutation in the tau protein gene. Arch Neurol 2003 1.49
18 Pathological gambling in Parkinson's disease: subthalamic oscillations during economics decisions. Mov Disord 2013 1.45
19 Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation. Lancet Neurol 2012 1.39
20 Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord 2010 1.34
21 Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson's disease. Mov Disord 2002 1.28
22 Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon 2013 1.27
23 Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003 1.23
24 Health-related quality of life in multiple system atrophy. Mov Disord 2006 1.11
25 Mutation screening of the DYT6/THAP1 gene in Italy. Mov Disord 2009 1.11
26 Dendrimer internalization and intracellular trafficking in living cells. Mol Pharm 2010 1.11
27 The diagnostic challenge of primary dystonia: evidence from misdiagnosis. Mov Disord 2010 1.10
28 A neurophysiological study of myoclonus in patients with DYT11 myoclonus-dystonia syndrome. Mov Disord 2008 1.06
29 Validation of the Italian version of the Movement Disorder Society--Unified Parkinson's Disease Rating Scale. Neurol Sci 2012 1.06
30 PINK1 heterozygous rare variants: prevalence, significance and phenotypic spectrum. Hum Mutat 2008 1.06
31 Long-term effects of pallidal or subthalamic deep brain stimulation on quality of life in Parkinson's disease. Mov Disord 2009 1.06
32 Replacement of dopaminergic medication with subthalamic nucleus stimulation in Parkinson's disease: long-term observation. Mov Disord 2009 1.05
33 Synergistic control of protein kinase Cgamma activity by ionotropic and metabotropic glutamate receptor inputs in hippocampal neurons. J Neurosci 2006 1.01
34 Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association. J Neurol 2012 0.99
35 Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome. Toxicon 2012 0.98
36 Inclusion and exclusion criteria for DBS in dystonia. Mov Disord 2011 0.97
37 Excessive daytime sleepiness in multiple system atrophy (SLEEMSA study). Arch Neurol 2011 0.97
38 Substantia nigra in Parkinson's disease: a multimodal MRI comparison between early and advanced stages of the disease. Neurol Sci 2013 0.97
39 Analysis of blink rate in patients with blepharospasm. Mov Disord 2006 0.97
40 Non-DYT1 early-onset primary torsion dystonia: comparison with DYT1 phenotype and review of the literature. Mov Disord 2006 0.97
41 Conflict-dependent dynamic of subthalamic nucleus oscillations during moral decisions. Soc Neurosci 2010 0.94
42 GCN5-dependent acetylation of HIV-1 integrase enhances viral integration. Retrovirology 2010 0.93
43 Targeting the brain: considerations in 332 consecutive patients treated by deep brain stimulation (DBS) for severe neurological diseases. Neurol Sci 2012 0.90
44 Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review. J Neurol 2013 0.90
45 Olfactory dysfunction in Parkinsonism caused by PINK1 mutations. Mov Disord 2009 0.90
46 Levodopa-induced dyskinesias and their management. J Neurol 2008 0.89
47 In vivo evidence for GABA(A) receptor changes in the sensorimotor system in primary dystonia. Mov Disord 2011 0.87
48 Primary focal hyperhidrosis in a new family not linked to known loci. Dermatology 2012 0.85
49 Presumptive myocarditis with ST-Elevation myocardial infarction presentation in young males as a new syndrome. Clinical significance and long term follow up. Cardiovasc Ultrasound 2011 0.85
50 Dopaminergic therapy and subthalamic stimulation in Parkinson's disease: a review of 5-year reports. J Neurol 2010 0.85
51 Phenotypic characterization of DYT13 primary torsion dystonia. Mov Disord 2004 0.84
52 "Gluing" phenotypes together: the case of GLUT1. Neurology 2011 0.84
53 Distinguishing scan without evidence of dopaminergic depletion patients with asymmetric resting tremor from Parkinson's disease: a clinical diagnosis of dystonia is required. Mov Disord 2010 0.83
54 Botulinum neurotoxins for post-stroke spasticity in adults: a systematic review. Mov Disord 2009 0.83
55 Subclinical sensory abnormalities in unaffected PINK1 heterozygotes. J Neurol 2008 0.83
56 Transient gender-related effects in Parkinson's disease patients with subthalamic stimulation. J Neurol 2009 0.83
57 Disability and profiles of functioning of patients with Parkinson's disease described with ICF classification. Int J Rehabil Res 2011 0.83
58 Deep brain stimulation for movement disorders. Considerations on 276 consecutive patients. J Neural Transm (Vienna) 2011 0.82
59 Designing clinical trials for dystonia. Neurotherapeutics 2014 0.82
60 Epidural premotor cortical stimulation in primary focal dystonia: clinical and 18F-fluoro deoxyglucose positron emission tomography open study. Mov Disord 2012 0.82
61 Clinical and neuropsychological correlates in two brothers with pantothenate kinase-associated neurodegeneration. Mov Disord 2005 0.82
62 Quantitative analysis of Tat peptide binding to import carriers reveals unconventional nuclear transport properties. J Biol Chem 2011 0.82
63 Frequency and phenotypes of LRRK2 G2019S mutation in Italian patients with Parkinson's disease. Mov Disord 2006 0.81
64 Alpha-synuclein gene duplication: marked intrafamilial variability in two novel pedigrees. Mov Disord 2013 0.80
65 Impact of nonmotor symptoms on disability in patients with Parkinson's disease. Int J Rehabil Res 2011 0.80
66 Advances in the genetics of primary torsion dystonia. F1000 Biol Rep 2010 0.80
67 Abnormal gating of somatosensory inputs in essential tremor. Clin Neurophysiol 2003 0.80
68 Clinical management of pain and fatigue in Parkinson's disease. Parkinsonism Relat Disord 2012 0.80
69 Relationships between disability, quality of life and prevalence of nonmotor symptoms in Parkinson's disease. Parkinsonism Relat Disord 2011 0.79
70 Cortical myoclonus in childhood and juvenile onset Huntington's disease. Parkinsonism Relat Disord 2012 0.79
71 Genome-wide association study in musician's dystonia: a risk variant at the arylsulfatase G locus? Mov Disord 2013 0.79
72 STN DBS in PD: selection criteria for surgery should include cognitive and psychiatric factors. Neurology 2006 0.79
73 Botulinum toxin for the management of adult patients with upper motor neuron syndrome. Toxicon 2009 0.79
74 Phenotypic variability of DYT1-PTD: does the clinical spectrum include psychogenic dystonia? Mov Disord 2002 0.78
75 Mood disorder following DBS of the left amygdaloid region in a dystonia patient with a dislodged electrode. Mov Disord 2008 0.78
76 Functioning and disability in Parkinson's disease. Disabil Rehabil 2010 0.77
77 Treatment with botulinum neurotoxin of gastrointestinal smooth muscles and sphincters spasms. Mov Disord 2004 0.77
78 Unique properties of botulinum toxins. Toxicon 2009 0.77
79 High frequency stimulation of the subthalamic nucleus is efficacious in Parkin disease. J Neurol 2005 0.76
80 Attentional networks in Parkinson's disease. Behav Neurol 2013 0.76
81 Treatment of outlet obstruction constipation in Parkinson's disease with botulinum neurotoxin A. Am J Gastroenterol 2003 0.76
82 Early visual memory deficits: a neuropsychological marker of GBA mutations in PD? Neurology 2012 0.76
83 Early versus delayed bilateral subthalamic deep brain stimulation for Parkinson's disease: need for long-term clinical trials. Mov Disord 2011 0.75
84 Can falls be prevented in Parkinson's disease? J Neurol Neurosurg Psychiatry 2007 0.75
85 Choice-option evaluation is preserved in early Huntington and Parkinson's disease. Neuroreport 2011 0.75
86 Pre-operative evaluations for DBS in dystonia. Mov Disord 2011 0.75
87 Concordance between severity of disease, prevalence of nonmotor symptoms, patient-reported quality of life and disability and use of medication in Parkinson's disease. Neurol Sci 2011 0.75
88 Guest editors' introduction. Mov Disord 2011 0.75
89 Ambiguous idiom processing in Parkinson's disease patients. Cogn Neuropsychol 2014 0.75
90 Normal cardiovascular reflex testing in patients with parkin disease. Mov Disord 2007 0.75
91 Rivastigmine in Parkinson's disease dementia. Expert Rev Neurother 2008 0.75
92 Diagnostic issues in childhood and adult dystonia. Expert Opin Med Diagn 2011 0.75
93 Effects of stimulation of the subthalamic nucleus on naming and reading nouns and verbs in Parkinson's disease. Neuropsychologia 2012 0.75
94 Low-voltage bilateral pallidal stimulation for severe meige syndrome in a patient with primary segmental dystonia: case report. Neurosurgery 2010 0.75
95 Cutaneous herpes zoster and implantable pulse generator. Neuromodulation 2009 0.75
96 Clinical presentation and progression of sporadic and familial primary torsion dystonia in Italy. Adv Neurol 2004 0.75
97 Reliability and validity of the range of motion scale (ROMS) in patients with abnormal postures. Pain Med 2014 0.75